Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melflufen plus dexamethasone in previously treated AL amyloidosis (Phase 1/2)
2018-002761-19Phase 2Terminated
- Sponsor
- Oncopeptides AB
- Start
- Jul 2019
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide in light-chain amyloidosis, sponsored by Oncopeptides AB. Primary endpoint: Phase 1 primary endpoints. Started Jul 2019; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2018-002761-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002761-19.